Mesenchymal stem cell abnormalities in patients with multiple myeloma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Leukemia and Lymphoma Année : 2007

Mesenchymal stem cell abnormalities in patients with multiple myeloma

Résumé

Osteolytic bone lesions are common in patients with multiple myeloma (MM), a clonal plasma cell disorder, and result from increased osteoclastic bone resorption and decreased osteoblastic bone formation. Because mesenchymal stem cells (MSCs) are committed towards cells of the osteoblast lineage, we compared the in vitro characteristics of MSCs from the bone marrow of 18 MM patients (MM-MSCs) and eight normal donors (ND-MSCs). MM-MSCs displayed deficient growth that could be explained in part by the reduced expression of several growth factor receptors on the surface of MM-MSCs compared with ND-MSCs. Receptor downregulation was observed on RT-PCR analysis. A major finding was an approximately fivefold higher expression of osteoblast inhibitor DKK1 at transcript and protein levels in MM-MSCs than ND-MSCs. These data suggest that defective osteoblast function in patients with advanced MM may be related not only to factors released by tumor myeloma cells but also to MSC abnormalities.
Fichier non déposé

Dates et versions

hal-03015586 , version 1 (19-11-2020)

Identifiants

Citer

L. Garderet, C. Mazurier, A. Chapel, I. Ernou, L. Boutin, et al.. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leukemia and Lymphoma, 2007, 48 (10), pp.2032-2041. ⟨10.1080/10428190701593644⟩. ⟨hal-03015586⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More